Abstract
Ancrod (Arvin) on slow intravenous administration converts fibrinogen into fibrin at a rate which does not cause intravascular thrombosis. The fibrin is eliminated from the circulation and the blood is thus rendered incoagulable. To test the efficacy of ancrod in the prevention of thrombosis after prosthetic replacement of the heart valves, the tricuspid valve was replaced with a polypropylene mitral valve in 17 calves, using cardiopulmonary bypass. Five calves were eliminated from the study. Eleven calves were treated with ancrod, and one untreated calf was used as a control. Four out of five prosthetic valves in calves treated with ancrod for up to 72 hours were free of thrombus formation, and one out of three at one week. In the long-term study, fibrinogen titres rose after varying intervals, in spite of continual treatment with ancrod. This `escape' of fibrinogen titres from the control of ancrod may be due to species resistance or to the development of immunity. Further study is in progress to elucidate this point and to gain further knowledge for the clinical application of ancrod.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell W. R., Bolton G., Pitney W. R. The effect of arvin on blood coagulation factors. Br J Haematol. 1968 Dec;15(6):589–602. doi: 10.1111/j.1365-2141.1968.tb01581.x. [DOI] [PubMed] [Google Scholar]
- Bonchek L. I., Braunwald N. S. Modification of thrombus formation on prosthetic heart valves by the administration of low molecular weight dextran. Ann Surg. 1967 Feb;165(2):200–205. doi: 10.1097/00000658-196702000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SHARP A. A., HOWIE B., BIGGS R., METHUEN D. T. Defibrination syndrome in pregnancy: value of various diagnostic tests. Lancet. 1958 Dec 20;2(7060):1309–1312. doi: 10.1016/s0140-6736(58)90579-8. [DOI] [PubMed] [Google Scholar]